

Special Issue

Testicular Cancer

Message from the Guest Editor

Testicular Cancer (TC) is the most commonly diagnosed malignant tumor in males between the ages of 16 and 40 years. The incidence of TC continues to rise, and the vast majority of TC patients are diagnosed with clinical stage I disease, either non-seminoma or seminoma testis. The aim of this Special Issue of *Cancers* is to address the following important clinical knowledge gaps regarding the diagnosis and management of clinical stage I TC: i) the impact of TC diagnosis on psychological and sexual wellbeing and fertility of patients; ii) the need for new and improved detection of prognostic markers to more accurately identify patients at the highest risk of relapse following orchiectomy; iii) controversies surrounding risk-adapted management of adjuvant treatment; and iv) the importance of long-term TC survivorship and monitoring of late side-effects. I sincerely hope this issue of *Cancers* will be read with great interest by clinicians, researchers, and patients.

Guest Editor

Dr. Joost L. Boormans
Erasmus MC, Rotterdam, Netherlands

Deadline for manuscript submissions

closed (30 November 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/46908

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)